Centene Posts Higher Revenue and Profit-to-Profit Earnings Lift for the Three-Month Reporting Period

Bottom line

- Centene Corporation filed 10-Q for the fiscal period identified as period-ended-2026-03-31, filed under accession 0001071739-26-000098 (CIK 0001071739, ticker CNC). - The top line, Revenue from Contract with Customer, Excluding Assessed Tax, was $44,655,000,000 USD for the three-month reporting period of the three months ended March 31, 2026, versus $42,489,000,000 USD for the prior-year comparative of the three months ended March 31, 2025, moving higher than the prior period. - A second revenue presentation, labelled Revenues, was $49,944,000,000 USD for the three months ended March 31, 2026, versus $46,620,000,000 USD for the three months ended March 31, 2025, also higher than the prior period.

- Operating Income (Loss) was $1,861,000,000 USD for the three months ended March 31, 2026, versus $1,534,000,000 USD for the three months ended March 31, 2025, remaining in profit and higher than the prior period. - Net Income (Loss) Attributable to Parent was $1,541,000,000 USD for the three months ended March 31, 2026, versus $1,311,000,000 USD for the three months ended March 31, 2025, remaining in profit and higher than the prior period. 63 per diluted share USD/SHARES for the three months ended March 31, 2025, remaining in profit and higher than the prior period.

- Source scope: the cited quarterly figures above are taken from the financial statements contained in the 10-Q filing of CENTENE CORP for period-ended-2026-03-31 under accession 0001071739-26-000098; the Item headings referenced inside the filing (Legal Proceedings at Item 1, Risk Factors at Item 1A, Unregistered Sales of Equity and Use of Proceeds at Item 2, Quantitative and Qualitative Disclosures About Market Risk and Controls and Procedures at Item 3, and Exhibits at Item 6, with Item 4 and Item 5 covering the remaining Part II sections) provide the surrounding context for these statements, and the Cautionary Statement on Forward-Looking Statements opens the filing.

- Cross-check note for the reader: a prior write-up on the same issuer, Centene Posts Higher Revenue and a Loss-to-Profit Swing on the Bottom Line for the Three-Month Reporting Period, with Year-to-Date Profitability Also Improving, frames a different presentation window; the present analysis is anchored strictly to the three-month reporting window of the three months ended March 31, 2026 versus the three months ended March 31, 2025 as filed under accession 0001071739-26-000098.

Financial performance

- Reported revenue from contracts with customers, excluding assessed tax, was $44,655,000,000 USD for the three-month reporting period the three months ended March 31, 2026, against $42,489,000,000 USD for the three months ended March 31, 2025, a higher top line on the year-over-year comparison. The separate Revenues line — the broader caption presented alongside the contract-with-customer figure — also moved higher, from $46,620,000,000 USD to $49,944,000,000 USD across the same two quarters. Both revenue captions point in the authorized upward direction; the filing does not break out which product lines or membership cohorts carried that lift, and The filing evidence does not disclose segment-level detail for this dimension.

applies to any attempt to split the gain by Medicaid, Medicare, Marketplace or commercial business. - Operating income was $1,861,000,000 USD for the three months ended March 31, 2026, versus $1,534,000,000 USD for the three months ended March 31, 2025. The authorized direction is increase, with the current quarter a profit and the prior-year quarter also a profit, so the comparison is profit to profit rather than a turnaround from a loss.

- Net income attributable to parent was $1,541,000,000 USD for the three months ended March 31, 2026, against $1,311,000,000 USD for the three months ended March 31, 2025; the authorized direction is increase, and again the comparison is profit to profit. 63 per diluted share USD/SHARES for the three months ended March 31, 2025. The authorized direction is increase, with both periods profitable on a per-share basis.

- This section's FACT catalog does not contain any sequential-quarter placeholder, so a quarter-versus-prior-quarter narrative is not supported here. The only comparison frames the catalog authorizes for these dimensions are the year-over-year views above. - The forward-looking cautionary text in Item 1A catalogs an unusually broad risk register — product pricing and actuarial soundness, medical-cost trend, government payor rate actions, ACA and eAPTC renewal timing, CMS Star ratings, contract reprocurements, information systems, impairments, macroeconomic conditions, tax matters, indebtedness covenants, and downgrade risk — but the filing does not translate that register into quantified guidance ranges for revenue, margin or earnings for the next quarter or the full year.

Forward-looking commentary in this 10-Q is therefore qualitative, not numerical. - The filing evidence contains no peer or industry comparison, so The filing evidence contains no peer or industry comparison. governs any attempt to benchmark Centene against other managed-care names in this section; the related CMS Energy and AOS earnings windows in the link inventory are not comparable revenue stories to this managed-care contract-revenue profile and are not used here.

No management transcript, sell-side note or consensus estimate is included in the file, so analyst expectation gaps cannot be derived from the supplied data, and any causal read on why revenue rose, or why EPS expanded, is left to The filing evidence does not attribute this change to any single cause. rather than narrated.

Operating drivers and segments

The reported top line for the three-month reporting period reached $44,655,000,000 USD under the contract-with-customer caption, against the prior-year comparative of $42,489,000,000 USD. The separate Revenues caption — which often captures items the contract-with-customer line excludes — printed at $49,944,000,000 USD for the current quarter versus $46,620,000,000 USD for the prior-year quarter. Both revenue labels point to a larger top line in the current period than in the prior-year comparative.

Operating Income (Loss), the consolidated profitability proxy that survives revenue and operating costs, was reported at $1,861,000,000 USD for the current three-month period, compared with $1,534,000,000 USD for the prior-year comparative. The current figure is a profit, the prior-year comparative is also a profit, and the direction of change is an increase.

No segment-level revenue, premium, service, or intersegment table is included in the quoted source narrative, so the contribution of the Medicaid, Medicare, Commercial, or Other reporting units to the consolidated movement cannot be read directly from the evidence. The only segment-coloured remark in the quoted text is the Magellan Health divestiture note, where the Company signed a definitive agreement to sell the remaining Magellan Health businesses and classified those operations inside the Other segment. The relative weight of that Other segment within the consolidated top line is not stated in the evidence.

The ratio of operating income to revenue is not stated in the evidence, and the filing does not provide a separate medical-benefit-ratio or operating-cost-ratio breakdown for the quarter, so an independent reading of margin expansion versus margin compression versus a roughly flat margin cannot be derived without numbers that are not in the catalog. The filing evidence does not attribute this change to any single cause.

The cautionary-statement and forward-looking passages treat future operating and financial performance, pricing actions, contract start dates, completed and future acquisitions and dispositions, and available cash resources as forward-looking subjects rather than as reported drivers. They are framed as assumptions and risk language, not as a quantified explanation of why the quarter's revenue or operating income moved. No management claim in the quoted narrative is tied to a specific revenue or operating-income figure for the period.

On the qualitative side, management points to competitive product design and pricing, accurate forecasting of health benefits and other operating expenses and reserves, the trajectory of medical costs, government payor rate adequacy and timing, and the broader social, economic, and political environment as forward-looking risk factors. None of these is presented in the quoted narrative as a measured cause of the reported revenue or operating-income direction. The Magellan Health disposal is described as a signed definitive agreement to sell the remaining Magellan Health businesses, with those operations sitting inside the Other segment, but the financial effect of that divestiture on the reported quarter is not quantified in the quoted text.

Independent cross-checks against peer or industry data are not available inside the filing. The filing evidence contains no peer or industry comparison.

Cash flow and capital

Reported facts - Operating cash flow for the three-month period came in positive, and it was higher than the prior-year comparative, which was also positive. - Investing cash flow for the three-month period was positive, a swing relative to the prior-year comparative, which was negative. - Financing cash flow for the three-month period was negative, and the cash outflow was larger than the prior-year comparative outflow, also negative. - Common-stock repurchases in the quarter were positive but lower than the prior-year comparative outflow for the same line. - Capital expenditures on property, plant, and equipment were positive and higher than the prior-year comparative. - The balance sheet shows cash and cash equivalents of $21,264,000,000 USD as of the balance sheet date of March 31, 2026 alongside long-term debt, excluding current maturities, of $16,308,000,000 USD at the same date.

Management explanations - Management notes that certain amounts in the consolidated financial statements and notes have been reclassified to conform to the current presentation, with no effect on net earnings or stockholders' equity as previously reported. - Management is evaluating the effect of the recent FASB guidance on disaggregation of income-statement expenses and on internal-use software capitalization, with effective dates for annual periods beginning after December of the cited year. - Management describes a master receivable purchase agreement covering stand-alone Part D risk-sharing program receivables from CMS, with a maximum outstanding purchase amount tied to the agreement and pricing referenced to the Secured Overnight Financing Rate plus a spread; proceeds were applied to the partial redemption of the company's Senior Notes due in December of the cited year. - Management also describes the agreement to sell the remaining Magellan Health businesses, classified as held for sale with the associated assets and liabilities reclassified on the Consolidated Balance Sheet as of the cited date.

Analyst inference - Operating cash flow generation strengthened year over year, consistent with the year-over-year direction in net income attributable to parent disclosed in earlier sections. - Investing cash flow swung from a use of cash to a source of cash, which on its face reduces the drag from the investing line, though The filing evidence does not attribute this change to any single cause.. - Financing cash outflow widened, with the reduction in common-stock repurchases running counter to the larger overall financing outflow, suggesting that other financing activities — such as the noted Senior Notes redemption — weighed more heavily on the line; The filing evidence does not attribute this change to any single cause.. - Capital spending stepped up from the prior-year quarter, while the balance sheet continued to carry a sizable long-term debt stack against the cash balance disclosed as of the period-end date.

Counter-evidence - The stronger operating cash flow and the swing to positive investing cash flow sit alongside a larger financing outflow and rising capital intensity, leaving the net cash position dependent on how those opposing lines offset. - The held-for-sale treatment of Magellan Health reclassifies prior balances into other current assets and accounts payable and accrued expenses, which can affect period-to-period comparisons of those balance-sheet captions.

Unknowns - The filing evidence does not provide a quantified bridge between operating, investing, and financing flows and the change in cash on the balance sheet for the three-month reporting period. - The filing evidence does not attribute the movements in operating, investing, financing, repurchase, or capital-expenditure lines to any single cause. The filing evidence does not attribute this change to any single cause. - The filing evidence contains no peer or industry comparison. The filing evidence contains no peer or industry comparison.

Peer and historical context

For the three-month reporting period, CENTENE CORP (CNC) delivered a pattern in which every top-line and bottom-line measure on the income statement moved in the same authorized direction against the prior-year comparative. Revenue from Contract with Customer, Excluding Assessed Tax was higher than the prior period at $44,655,000,000 versus $42,489,000,000, and the parallel Revenues line similarly registered an increase to $49,944,000,000 from $46,620,000,000. Operating Income (Loss) also rose year over year, climbing from $1,534,000,000 to $1,861,000,000, while Net Income (Loss) Attributable to Parent followed the same authorized transition, profit to profit, moving up to $1,541,000,000 from $1,311,000,000. On the cash side, Net Cash Provided by (Used in) Operating Activities likewise strengthened, with current-period operating cash flow of $4,366,000,000 sitting above the prior-period figure of $1,510,000,000. Taken together, those authorized movements describe a quarter in which revenue, operating profit, net profit, and operating cash generation all stepped higher against the prior-year quarter, even though the filing evidence contains no peer or industry comparison and does not attribute the change to any single cause.

The filing evidence contains no peer or industry comparison, so any read-across to other managed-care issuers — for example the pattern described in Centene Posts Higher Revenue and a Loss-to-Profit Swing on the Bottom Line for the Three-Month Reporting Period, with Year-to-Date Profitability Also Improving — cannot be substantiated from the cited numbers alone. The quarter-versus-prior-year direction is uniform across the authorized comparisons, which limits the room for an offsetting counter-narrative; the only meaningful caveat is that revenue growth, operating income growth, net income growth, and operating cash flow growth are reported as parallel authorized increases rather than as independent drivers, and The filing evidence does not attribute this change to any single cause.. Because no segment, premium, or medical-loss-ratio disclosure is part of this section's catalog, there is no internal cross-check that would let a reader reconcile the four authorized increases against each other, and the absence of a prior-period within-year comparison (such as a sequential or year-to-date frame) means the historical view is restricted to the single year-over-year axis shown above.

- The peer set relevant to CENTENE CORP is not enumerated in the filing for this section. - The historical frame is limited to the three-month reporting period versus the three months ended March 31, 2025, with no earlier comparable windows supplied. - The filing's cautionary and forward-looking language, captured under Item 6, does not modify the authorized year-over-year directions cited above.

Scenario analysis

Under the base path, CENTENE CORP (CNC) sustains the directionality visible in the three-month reporting period the three months ended March 31, 2026 against the prior-year comparative the three months ended March 31, 2025, with Revenue from Contract with Customer, Excluding Assessed Tax moving from $42,489,000,000 USD to $44,655,000,000 USD (higher than the prior period) and Revenues tracking the same direction, moving from $46,620,000,000 USD to $49,944,000,000 USD (higher than the prior period). Net Income (Loss) Attributable to Parent moves from $1,311,000,000 USD to $1,541,000,000 USD (higher than the prior period; a profit-to-profit transition), with Operating Income (Loss), Earnings Per Share Diluted and Net Cash Provided by (Used in) Operating Activities each moving from a positive prior-period base to a higher positive current-period figure. Net Cash Provided by (Used in) Investing Activities moves from negative prior-year usage to a positive current-period source, while Net Cash Provided by (Used in) Financing Activities remains negative on both sides but lower than the prior period, and Payments to Acquire Property, Plant, and Equipment move from a positive prior-period figure to a higher positive current-period figure against Payments for Repurchase of Common Stock moving from a positive prior-period figure to a lower positive current-period figure. Management's Item 6 cautionary-statement framing on forward-looking commentary, together with the receivable-sale, restricted-deposit and securities disclosures described in the filing, is taken at face value with no incremental reinterpretation. The filing evidence does not attribute this change to any single cause.

Under the upside path, the same revenue and bottom-line directions deepen, with $44,655,000,000 USD printing above the base assumption and $49,944,000,000 USD extending the contract-revenue gain, while $1,541,000,000 USD widens the gap over $1,311,000,000 USD within the profit-to-profit transition. Operating Income (Loss) and Earnings Per Share Diluted are read as stronger than the base path on the same directionality, Net Cash Provided by (Used in) Operating Activities prints above the base path, and Net Cash Provided by (Used in) Investing Activities moves further from the negative prior-period usage into a more positive current-period source. Net Cash Provided by (Used in) Financing Activities remains negative on both sides but lower than the prior period, Payments to Acquire Property, Plant, and Equipment move to a higher positive current-period figure than the base path implies, and Payments for Repurchase of Common Stock move to a lower positive current-period figure than the base path implies. The upside retains the Item 6 forward-looking language and the receivable-sale mechanics as boundary conditions rather than drivers. The filing evidence does not attribute this change to any single cause.

Under the downside path, the same directions hold but at reduced magnitudes, with $44,655,000,000 USD printing below the base assumption while still above $42,489,000,000 USD, $49,944,000,000 USD tracking the same softer-but-still-higher direction against $46,620,000,000 USD, and $1,541,000,000 USD remaining above $1,311,000,000 USD within the profit-to-profit transition but at a narrower margin than the base path. Operating Income (Loss), Earnings Per Share Diluted and Net Cash Provided by (Used in) Operating Activities remain higher than the prior period but trail the base path, Net Cash Provided by (Used in) Investing Activities still moves from negative prior-period usage to a positive current-period source but at a smaller magnitude, and Net Cash Provided by (Used in) Financing Activities remains negative on both sides but lower than the prior period at a smaller improvement. Payments to Acquire Property, Plant, and Equipment and Payments for Repurchase of Common Stock hold their respective directions at softer magnitudes than the base path. The filing evidence does not attribute this change to any single cause. The filing evidence contains no peer or industry comparison. The filing evidence does not disclose segment-level detail for this dimension.

Risks and what to watch

The forward-looking risks disclosed in Item 1A frame the period's higher revenue and profit-to-profit transition against an unusually wide set of contingency variables. Because the filing's risk factor discussion is itself a forward-looking narrative rather than a quantified table, the risk dimension here is qualitative: the reader should treat every authorized comparison above as conditional on the assumptions spelled out in the cautionary statement in Item 6 and the legal-proceedings and risk-factor updates in Item 1 through Item 4. No filing-attested counter-evidence in this section's narrative argues against the authorized directions, so the comparisons stand as reported; readers should not infer confirmation from silence, only that the filing does not rebut them.

Reported facts limited to this section are the topline and bottom-line values for the three-month reporting period and the prior-year comparative. Revenue from Contract with Customer, Excluding Assessed Tax was $42,489,000,000 USD for the three months ended March 31, 2025 and $44,655,000,000 USD for the three months ended March 31, 2026. The separate Revenues line was $46,620,000,000 USD for the three months ended March 31, 2025 and $49,944,000,000 USD for the three months ended March 31, 2026. Net Income (Loss) Attributable to Parent was $1,311,000,000 USD for the three months ended March 31, 2025 and $1,541,000,000 USD for the three months ended March 31, 2026. The source narrative adds context on receivables derecognition, investment portfolio composition including U.S. government and agency mortgage-backed securities, and the use of receivables-sale proceeds for partial redemption of the Company's Senior Notes due December, but it does not quantify the redemption, the loss on sale, or any unrealized gain or loss position; those omissions should be tracked rather than guessed.

Counter-evidence and management explanation: the narrative does not attribute the topline or bottom-line change to any single cause, so no driver story should be inferred from the filing alone. Management's explanation in the source passages focuses on accounting policy for the sale of receivables and on the composition and credit-rating profile of the investment portfolio, which is adjacent to but not a direct explanation of the quarter's revenue or net income movement. The legal-proceedings and exhibits sections are referenced rather than reproduced here.

Analyst inference is constrained to the authorized directions: top-line growth on both revenue lines, a profit-to-profit higher bottom line, higher operating cash flow and investing cash flow, lower financing cash flow, higher common stock repurchases and higher property, plant, and equipment spending, with diluted EPS profit-to-profit higher. No causality may be layered onto these directions.

Unknowns to flag for the next period include: the segment-level mix behind the revenue change, any updated legal-proceedings accrual from the matters referenced in Item 1, the realized loss on the receivables sale and the remaining balance of the redeemed Senior Notes tranche, the unrealized gain or loss roll-forward on the investment portfolio, and any update to the risk-factor catalog. The filing evidence does not disclose segment-level detail for this dimension, and the filing evidence contains no peer or industry comparison.

For peer context, Centene Posts Higher Revenue and a Loss-to-Profit Swing on the Bottom Line for the Three-Month Reporting Period sits inside the same insights category and may help frame how this quarter's profit-to-profit transition compares with the headline framing of that peer post.